{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Riedell PA"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["669-676"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9547952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(10)"],"pubmed_abstract":["Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective study among centers that prescribe either commercial product to evaluate usage patterns, safety and efficacy outcomes, and resource utilization. Data collection included all patients from 8 US centers who underwent apheresis between May 1, 2018, and July 31, 2019. Patient selection, toxicity management, and disease assessment followed institutional practices. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy conse"],"journal":["Transplantation and cellular therapy"],"pubmed_title":["Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas."],"pmcid":["PMC9547952"],"funding_grant_id":["UL1 TR002494","P30 CA008748"],"pubmed_authors":["Bachanova V","Schachter L","Schuster SJ","Pennisi M","Flores OA","Hwang WT","Ahmed N","Oluwole OO","Brower J","McGuirk JP","Bharucha K","Riedell PA","Maziarz RT","Perales MA","Porter DL","Bishop MR","Nastoupil LJ","Dholaria BR"],"additional_accession":[]},"is_claimable":false,"name":"Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.","description":"Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective study among centers that prescribe either commercial product to evaluate usage patterns, safety and efficacy outcomes, and resource utilization. Data collection included all patients from 8 US centers who underwent apheresis between May 1, 2018, and July 31, 2019. Patient selection, toxicity management, and disease assessment followed institutional practices. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy conse","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-29T14:04:42.475Z","creation":"2025-04-04T03:00:34.938Z"},"accession":"S-EPMC9547952","cross_references":{"pubmed":["35850429"],"doi":["10.1016/j.jtct.2022.07.011"]}}